Jump to section
To automate the design and execution of bioprocesses.
Bioprocesses – the use of living cells or their components to create biomaterial products – is a vital tool in the fight against environmental crisis, for the treatment of disease and for clean chemical manufacture. But its combination of analytical equipment, on-line sensors and manual interventions generate swamps of data that can be painstaking to analyse. Invert gathers data from all these sources into one place, facilitating swift but effective analysis across different scales.
Invert’s goal is to automate both the design and execution of bioprocesses, speeding up progress in this vital field. Its technology eliminates data silos by connecting data in production, allowing teams to perform advanced cross-source analytics without writing code. Data scientists are freed from data management or migrations, all handled by Invert, leaving them to focus on providing actionable insights.
Invert is designed to have utility across a range of business sizes from bioprocesses startups to established biopharma players. The company is Y combinator backed and currently focussed on growing its team to develop its product.
Freddie
Company Specialist at Welcome to the Jungle
Jul 2024
$20.2m
EARLY VC
This company has top investors
Mads Ingwar
(Co-Founder)Co-Founder of Kvasir Technologies. Chair of the Board at Leap Beyond Analytics. Former Partner, NordREE at Think Big Analytics.
Holger Hjorth Thorup
(Co-Founder)Founded Venncal. Co-founder & CTO at Pelion. Former VP of Engineering at ZeroNorth.
Rob Lambert
(Co-Founder)Founder of the Leap Beyond Group. Former Principal Manager and Data Scientist at Think Big. Previously Manager and Data Scientist at KPMG.
Martin Tromp Permin
(Co-Founder)Co-founder and CEO of Pelion. Worked in Business Development & Growth at Hive. Former Partnerships & Marketing Specialist at Airbnb.